We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byBrandi Vince
Modified about 1 year ago
Leadership. Knowledge. Community. Introduction Canadian Cardiovascular Society Antiplatelet Guidelines
Objectives Interpret the Canadian Cardiovascular Society Guideline for the Use of Antiplatelet Therapy in the Outpatient Setting recommendations regarding the use antiplatelet therapy for the prevention of vascular events. Recognize the scope of the Guideline. Interpret the Class of Recommendation and Level of Evidence used in the Guideline. Evaluate the rationale, mandate and target audience for the development of the guidelines. Acknowledge the contribution of the Canadian Cardiovascular Society, The Thrombosis Interest Group of Canada and the Authors to the development of the Guidelines © TIGC
Thrombosis Interest Group of Canada Le Groupe de Travail sur la Thrombose du Canada B
Rationale Clinicians need clear guidance on the use of all risk prevention strategies to reduce the burden of ischemic vascular disease. Lipids Hypertension Diabetes Disease states Coronary, Cerbrovascular, Peripheral Arterial © TIGC
Mandate/Target Mandate To provide an evidence based, treatment focused guideline for the use of antiplatelet drugs in the outpatient setting. Target audience All health care professionals who manage patients at risk of vascular ischemic events. © TIGC
CCS Antiplatelet Guideline committee Acute Coronary Syndrome/ Percutaneous Coronary Intervention Jean FrancoisTanguay Robert Welsh Michael Love Stable CAD Anil Gupta Pierre Theroux Cerebrovascular disease Ashfaq Shuaib Phil Teal Peripheral Arterial Disease Andre Roussin Thomas Lindsay Surgical Vascular Disease Raymond Cartier Thomas Lindsay Diabetes Maria Kraw Rémi Rabasa-Lhoret Special Topics Heart Failure Alan D Bell, James Douketis Chronic Kidney Disease Neesh Pannu, Alan D Bell Pregnancy and Lactation Wee Shian Chan Surgical /BleedingManagement James Douketis, Graham Turpie Antiplatelet agents + Warfarin James Douketis, Graham Turpie Antiplatelet Drug Interactions Alan D Bell, Wee Shian Chan Primary Prevention Alan D Bell James Douketis © TIGC
Class of recommendationLevel of evidence I: I: Evidence and/or general agreement that a given diagnostic procedure/treatment is beneficial, useful and effective A: Data derived from multiple randomized clinical trials or meta-analyses IIa: Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the treatment with the weight of evidence in favour B: Data derived from a single randomized clinical trial or large nonrandomized studies IIb: Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the treatment with the usefulness/efficacy less well established C: Consensus of opinion by experts and/or small studies, retrospective studies, and registries III: Evidence that the treatment is not useful and in some cases may be harmful © TIGC
Educational modules ACS and PCI Stable CAD Cerebrovascular Disease Peripheral Arterial Disease Primary Prevention Diabetes Heart Failure © TIGC Chronic Kidney Disease Concomitant PPI Concomitant NSAID Concomitant Warfarin Minor Bleeding Pregnancy and Lactation Perioperative Management Guideline Pearls Use of antiplatelet agents in:
RECOMMENDATIONS Canadian Cardiovascular Society Anti Platelet Guideline 2010 Alan D. Bell, MD, CCFP; Raymond Cartier, MD; Wee Shian Chan, MD, FRCP; James.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
ACC/AHA 2006 guidelines on the management of PAD.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines PERIOPERATIVE MANAGEMENT OF ANTIPLATELET THERAPY Working Group:
Estimate of Certainty (Precision) of Treatment Effect Level of evidence of B or C does not imply that recommendation is weak. LEVEL A Multiple populations.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines MANAGEMENT OF ANTIPLATELET THERAPY IN ASSOCIATION WITH MINOR.
Leadership. Knowledge. Community. Guideline Pearls Canadian Cardiovascular Society Antiplatelet Guidelines.
Historical perspective It all started with Aspirin….
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines INTERACTION BETWEEN CLOPIDROGEL AND PROTON PUMP INHIBITORS Working.
1 ESC/EAS 2011 Guidelines for the management of dyslipidemias
Leadership. Knowledge. Community. Antiplatelet Therapy for the Secondary Prevention of Cerebrovascular Disease Working Group: Ashfaq Shuaib, MD, FRCP;
Guidelines for the Primary Prevention of Stroke. A Guideline for Healthcare Professionals From the American Heart Association & American Stroke Association.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines USE OF ANTIPLATELET THERAPY IN WOMEN WHO ARE PREGNANT OR BREASTFEEDING.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines Antiplatelet Therapy for Vascular Prevention in Patients with.
Leadership. Knowledge. Community. Antiplatelet Therapy for the Primary Prevention of Vascular Events Working Group: Alan D. Bell, MD, CCFP and James D.
Myocardial Ischemia: Concepts in Management Topics in Clinical Medicine February 14, 2007.
Through its Quality efforts, the is… Supporting the appropriate use of new, transformational technologies and therapies Moving from a volume-to-value.
Leadership. Knowledge. Community. Antiplatelet Therapy for Secondary Prevention Beyond One Year Following ACS or PCI Working Group: Anil Gupta MD, FRCPC,
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines HEART FAILURE Working Group: Alan D. Bell, MD, CCFP; James D.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Slide Source: Lipids Online Slide Library CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations.
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
ADULT CARDIOLOGY IN PRIMARY CARE Mary I. Jones, FNP-C, MSN, MHSA Piedmont Heart Institute.
The Primary and Secondary Prevention of Cardiovascular Disease Per Olav Vandvik, MD, PhD A. Michael Lincoff, MD Joel M. Gore, MD David Gutterman, MD, FCCP.
1 Guidelines Applied to Practice (GAP) American College of Cardiology, Puerto Rico Chapter.
CV Update – Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet – 27/01/09 Dr Ameet Bakhai, FRCP – Cardiologist, Clinical Trials, Health.
Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.
10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines
Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Project Goals Enhance culture within cardiology practice that data is important. – Decreased variation in the practice. Fix a problem at a local level.
? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Case study - patient presenting with newly diagnosed NVAF with prior CAD Full Prescribing Information is provided at the end of this presentation EUAPI581k;
Optimal Timing of PCI in ACS Patrick Hildbrand. Trends and Prognosis in ACS Furman MI, JACC 2001, 37: Hospital 1 year.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.
© 2017 SlidePlayer.com Inc. All rights reserved.